Summary
From 1984 to 1987, we conducted a series of chemotherapy trials to assess their efficacy and impact on survival in patients with inoperable hepatocellular carcinoma. A total of 18 patients were treated with etoposide at a dose of 200 mg/m2 given on days 1–3 every 3 weeks for a maximum of 8 courses. No response was observed in any of the 18 patients studied. A further trial using epirubicin at doses of 40 and 75 mg/m2 again showed no evidence of a tumor response in 14 consecutive patients. The dose of epirubicin was further escalated to 90 mg/m2. Of the 33 patients treated, 1 (3%) achieved a complete response and 2 (6%) showed a partial response. Although the overall median survival amounted to only 72 days, the survival of the three responders was 15, 13, and 12 months, respectively. Therefore, we believe that the tumor response to epirubicin may be dose-dependent. However, the toxicity was also dose-dependent. To improve the therapeutic index we are currently evaluating the impact of intrahepatic artcrial injection of a lipiodol-epirubicin emulsion.
Similar content being viewed by others
References
Bonfante, V, Villani F, Bonadonna G (1982) Toxic and therapeutic activity of 4′-epi-doxorubicin. Tumori 68:105
Cancer Registry (1986) Medical and Health Department, Hong Kong Government
Lee NW, Wong J, Ong GB (1982) The surgical management of primary carcinoma of the liver. World J Surg 6:66
Lee, YJ, Staquet M, Simon R, Catane R, Muggia F (1979) Two-stage plans for patient accrual in phase II cancer clinical trials. Cancer Treat Rep 63:1721
Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP16 with Adriamycin. Cancer 51:206
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment Cancer 47:207
Ong GB, Chan PK (1976) Primary carcinoma of liver. Surg Gynecol Obstet 143:31
Thompson HH, Tompkins RK, Longmire WP Jr (1983) Major hepatic resection. A 25-year experience. Ann Surg 197:375
Tsuzuki T, Ogata Y, Iida S, Shimazu M (1984) Hepatic resection in 125 patients. Arch Surg 119:1025
Von Hoff DD, Layard, MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shiu, W.C.T. Primary liver cancer in Hong Kong. Cancer Chemother. Pharmacol. 31 (Suppl 1), S143–S145 (1992). https://doi.org/10.1007/BF00687124
Issue Date:
DOI: https://doi.org/10.1007/BF00687124